Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BG-C9074
- Development stage
- Phase 3
- Lead developer
- BeiGene
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
BG-C9074 is an investigational antibody-drug conjugate (ADC) that targets the B7-H4 protein, which is broadly expressed in various solid tumors, including breast and gynecologic cancers. The drug consists of a monoclonal antibody directed against B7-H4 linked to a cytotoxic payload. Upon administration, the antibody moiety binds specifically to B7-H4 on tumor cells, facilitating internalization and subsequent release of the cytotoxic agent within the cancer cell, leading to cell death[1][2][8]. BG-C9074 is currently being evaluated as monotherapy and in combination with tislelizumab (a PD-1 inhibitor) in Phase 1 clinical trials for advanced solid tumors[2][3][5][7]. The primary developer is BeiGene, with initial development by Duality Biologics.
- Other names
- anti-B7-H4 antibody drug conjugate BG-C9074anti-B-7-H4 antibody drug conjugate BG-C9074anti-B 7-H4 antibody drug conjugate BG-C9074
02
Targets
VTCN1 (V-set domain containing T cell activation inhibitor 1)
Beyond the preview
Go deeper on BG-C9074.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BG-C9074.